Renaissance Technologies LLC Sells 109,114 Shares of Rapport Therapeutics, Inc. $RAPPMarket Beat·1 day ago, 03:40 AMRAPP0.00%UBS0.00%
Rapport Therapeutics CEO Abraham Ceesay sells 51,499 shares worth $2.41 millionPUBT·Aug 12 at 03:36 PMRAPP0.00%
Rapport Therapeutics (NASDAQ:RAPP) Given New $66.00 Price Target at HC WainwrightMarket Beat·Aug 12 at 12:24 PMRAPP0.00%
Douglas Tsao Boosts Rapport Therapeutics Price Target to $66 on Strong RAP-219 Differentiation and Robust Phase 2 DataTip Ranks·Aug 12 at 11:55 AMRAPP0.00%
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Given Average Rating of "Moderate Buy" by BrokeragesMarket Beat·Aug 7 at 05:14 AMRAPP0.00%
Rapport Therapeutics Q2 FY26 net loss widens to $56.6 million; R&D expense more than doubled to $51.4 millionPUBT·Aug 5 at 06:18 AMRAPP0.00%
Rapport Therapeutics CEO Abraham Ceesay sells 2,210 shares worth $92,999.37PUBT·Jul 29 at 03:05 PMRAPP0.00%
Rapport Therapeutics (NASDAQ:RAPP) Stock Price Up 5.4% - Time to Buy?Market Beat·Jul 17 at 11:00 AMRAPP0.00%
RAP-219’s Differentiated Mechanism Supports Unchanged $65 Price Target and Reiterated Buy on Rapport TherapeuticsTip Ranks·Jul 16 at 05:35 AMRAPP0.00%
Rapport Therapeutics CEO Abraham Ceesay sells 8,210 common shares worth $328,018PUBT·Jul 15 at 03:15 PMRAPP0.00%
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Given Consensus Recommendation of "Moderate Buy" by BrokeragesMarket Beat·Jul 13 at 05:14 AMRAPP0.00%GS-C0.00%
Rapport Therapeutics CEO Abraham Ceesay disposes of common shares worth $327,031.55PUBT·Jul 1 at 03:05 PMRAPP0.00%
Does Truist’s New RAPP Coverage Subtly Reframe Rapport Therapeutics’ Long-Term Credibility Story (RAPP)?Simplywall·Jun 26 at 03:06 AMTFC0.00%RAPP0.00%
1 Reason Rapport Therapeutics (RAPP) Looks Pricey Following Truist Buy CoverageSimplywall·Jun 25 at 02:03 AMRAPP0.00%
